The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer.
 
Arturo Loaiza-Bonilla
No Relationships to Disclose
 
Mark H. O'Hara
No Relationships to Disclose
 
Maryann Redlinger
No Relationships to Disclose
 
Nevena Damjanov
No Relationships to Disclose
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Irina Vasilevskaya
No Relationships to Disclose
 
Mark Alan Rosen
No Relationships to Disclose
 
Daniel F Heitjan
No Relationships to Disclose
 
Ravi K. Amaravadi
No Relationships to Disclose
 
Peter J. O'Dwyer
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals
Consulting or Advisory Role - Five Prime Therapeutics; Genentech
Research Funding - BMS, Pfizer, Novartis, Genentech, Mirati, Celgene, GSK, BBI
Expert Testimony - Lilly